Skip to content

The effect of esketamine on postpartum depression of parturients after cesarean delivery

The effect of esketamine on postpartum depression of parturients after cesarean delivery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100045498
Enrollment
Unknown
Registered
2021-04-17
Start date
2020-07-01
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postpartum depression

Interventions

Es-ketamine group:After the block level is stabilized, a single dose of esketamine 0.15 mg/kg is applied intravenously before skin incision
Control group:After the block level is stabilized, an equal volume of normal saline is injected intravenously before skin incision

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
21 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1. Aged 21 to 35 years old, ASA I-II level with term singleton pregnancy. 2. No circulatory, respiratory, endocrine, and blood system disease; 3. No contraindications to intraspinal anesthesia, no and normal preoperative monitoring of fetal heart rate; 4. Plan to perform elective cesarean delivery; 5. Agree to participate in the study and sign the informed consent form for clinical research.

Exclusion criteria

Exclusion criteria: 1. Previous history of mental illness, use of psychotropic drugs, neurological diseases such as epilepsy, and suicidal intention or suicide; 2. History of drug, alcohol, or opioid abuse; 3. Application of monoamine oxidase inhibitor treatment within 14 days; 4. Participate in other clinical studies; 5. Suffering from severe heart disease, cerebral disease, liver disease or kidney disease; 6. Allergy to esketamine or any contraindications to combined spinal-epidural anesthesia; 7. With serious pregnancy complications: high blood pressure, eclampsia and preeclampsia; 8. Illiteracy, language disability, or communication difficulty due to hearing or vision impairment; 9. Parturient with full stomach.

Design outcomes

Primary

MeasureTime frame
EPDS(Edinburgh Postnatal Depression Scale);

Secondary

MeasureTime frame
VAS (visual analog scale);Related complications;Vital signs and Apgar score;interleukin-2;interleukin-4;interleukin-6;interleukin-10;tumor necrosis factor-alpha;interferon-gama;

Countries

China

Contacts

Public ContactJi Fuhai

The First Affiliated Hospital of Soochow University

jifuhai@suda.edu.cn+86 13656207331

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026